Miglitol

Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets[1][2][3][4].

Product Specifications

CAS Number

[72432-03-2]

Product Name Alternative

BAY1099; BAY-m1099

UNSPSC

12352005

Hazard Statement

H315, H319

Target

AMPK; Glycosidase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Miglitol.html

Purity

98.0

Solubility

H2O : ≥ 200 mg/mL

Smiles

O[C@@H]1[C@@H](CO)N(CCO)C[C@H](O)[C@H]1O

Molecular Formula

C8H17NO5

Molecular Weight

207.22

Precautions

H315, H319

References & Citations

[1]Fukaya, N., et al., The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats. Eur J Pharmacol, 2009. 624 (1-3) : p. 51-7.|[2]Hirata, A., et al., Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res, 2009. 41 (3) : p. 213-20.|[3]Scott LJ, et al. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000 Mar;59 (3) :521-49. |[4]Aoki C, et al. Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. J Pharmacol Sci. 2012;120 (2) :121-8.